TEX10 and melanoma: A third cohort was added, in which patients received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg Q3W for four doses, followed by nivolumab 3 mg/kg Q2W (NIVO3 + IPI1; n = 20), based on melanoma studies suggesting that NIVO3 + IPI1 is better tolerated than NIVO1 + IPI3.